One, two, three or more pathways for platelet aggregation.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Acta medica Scandinavica. Supplementum

• Publication date

  2009-04-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/J.0954-6820.1980.TB10931.XPMID 6779505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interference of bromophenacyl bromide with platelet phospholipase A2 activity induced by thrombin and by the ionophore A23187.

  1980cited by this paper
• Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs.

  1979cited by this paper
• Anti‐inflammatory and platelet anti‐aggregant activity of phospholipase‐A2 inhibitors

  1979cited by this paper
• The role of platelet-activating factor in platelet aggregation

  1979cited by this paper
• Ionophore A-23187- and thrombin-induced platelet aggregation: independence from cycloxygenase products.

  1978cited by this paper
• The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines.

  1978cited by this paper
• Carrageenan and thrombin trigger prostaglandin synthetase‐independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors *

  1977cited by this paper
• Structural analysis of purified platelet-activating factor by lipases

  1977cited by this paper
• Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion

  1977cited by this paper
• Sodium arachidonate can induce platelet shape change and aggregation which are independent of the release reaction.

  1976cited by this paper
• In Vitro and in Vivo Functions of Thrombin-Treated Platelets

  1976cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper
• Histidine at the active site of phospholipase A2.

  1974cited by this paper
• Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction.

  1974cited by this paper
• Platelet aggregation and release: effects of low concentrations of thrombin or collagen.

  1973cited by this paper
• A new potential mediator of arterial thrombosis whose biosynthesis is inhibited by aspirin.

  1973cited by this paper
• Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2.

  1973cited by this paper

• Preventive effect of polydatin against thrombosis: and its mechanism

  2011cites this paper
• Therapeutic range for oral anticoagulant treatment

  2010cites this paper
• Responsiveness to aspirin in patients with unstable angina pectoris by whole blood aggregometry

  2009cites this paper
• Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance

  2004cites this paper
• Antiplatelet and anticoagulant effects of "HN-11 500," a selective thromboxane receptor antagonist.

  2001cites this paper
• Platelet-activating-factor-hydrolyzing phospholipase C in the salivary glands and saliva of the mosquito Culex quinquefasciatus.

  2001cites this paper
• Insulin Increases Guanosine-3′ ,5′-Cyclic Monophosphate in Human Platelets: A Mechanism Involved in the Insulin Anti-Aggregating Effect

  1994cites this paper
• Aspirin fails to inhibit platelet aggregation in sheep.

  1993cites this paper
• Platelet-activating Factor

  1991cites this paper
• Toward an optimal "antiplatelet" dose of aspirin: Preliminary observations.

  1991cites this paper
• Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo

  1989cites this paper
• Insulin Directly Reduces Platelet Sensitivity to Aggregating Agents: Studies In Vitro and In Vivo

  1988cites this paper
• Synergistic antiplatelet and antithrombotic effects of a prostacyclin analogue (iloprost) combined with a thromboxane antagonist (sulotroban) in guinea pigs and rats.

  1988cites this paper
• The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).

  1988cites this paper
• Detection of small inhibitory effects of acetylsalicylic acid (ASA) by platelet impedance aggregometry in whole blood.

  1988cites this paper
• Physiology of Blood Coagulation and Hemostasis

  1987cites this paper
• Evidence for a Role for Na+‐H+ Exchange in Activation of Human Platelets by PAF

  1987cites this paper
• Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis

  1987cites this paper
• Bronchopulmonary Pharmacology of PAF-Acether

  1987cites this paper
• Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human plateletsin vitro

  1986influential citation
• Mechanism of PAF-induced platelet aggregation in man.

  1986cites this paper
• Inhibitory effects of three new synthetic compounds on human platelet aggregation.

  1986cites this paper
• Effect of Indomethacin and Dazoxiben on Intravascular Platelet Aggregation in the Anaesthetized Rabbit

  1986cites this paper
• Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man.

  1986cites this paper
• Enhancement of collagen-induced aggregation of platelets in whole blood.

  1986cites this paper
• Platelet activation in normo- and hyperlipoproteinemias

  1986cites this paper
• Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) – Effects of Acetylsalicylic Acid and External Ionized Calcium

  1985cites this paper
• Functional and Biochemical Characterization of Immunologically Derived Equine Platelet-Activating Factor

  1985cites this paper
• Role of paf-acether and related ether-lipid metabolism in platelets.

  1985cites this paper
• Pharmacological studies of pulmonary anaphylaxisin vitro: A review

  1985cites this paper
• Drugs and Platelet Activation in Migraine and Transient Ischemic Attacks

  1985cites this paper
• Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation

  1985cites this paper
• Biochemical mechanisms in 5-hydroxytryptamine-induced human platelet aggregation

  1985cites this paper
• In vivo arterial platelet-vessel wall interaction and thrombosis: induction, on-line registration and ultrastructural control.

  1985cites this paper
• Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid.

  1985cites this paper
• PAF-Acether May Not Mediate the Third Pathway of Platelet Aggregation since Self-Desensitization Reduces the Effects of Low Thrombin but Enhances Those of Convulxin

  1985cites this paper
• Platelet release reaction and aggregation induced by canatoxin, a convulsant protein: evidence for the involvement of the platelet lipoxygenase pathway

  1985cites this paper
• Platelet‐activating factor is a weak platelet agonist: Evidence from normal human platelets and platelets with congenital secretion defects

  1984cites this paper
• A Comparison of Spontaneous Platelet Aggregation in Whole Blood with Platelet Rich Plasma: Additional Evidence for the Role of ADP

  1984cites this paper
• Studies on platelet-activating factor (PAF)

  1984cites this paper
• Effect of eicosatetraenyl (3-aminopropyl) phosphonate (URI-73A) on platelet aggregation and arachidonic acid metabolism.

  1983cites this paper
• Modulation of equine platelet function by diethylcarbamazine (DEC).

  1983cites this paper
• Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets.

  1983cites this paper
• Technical considerations for platelet aggregation and related problems

  1983cites this paper
• Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'.

  1983cites this paper
• Technical considerations for platelet aggregation and related problems.

  1983cites this paper
• On the relationship between aggregation and cyclic nucleotides in platelets treated with betaadrenoceptor blocking drugs.

  1983cites this paper
• Aggregation of equine platelets by PAF (platelet-activating factor)

  1983cites this paper
• Biology and biochemistry of platelet-activating factor

  1983cites this paper
• Platelet Hyperaggregability in Ischemic Cerebrovascular Disease and Effects of Aspirin

  1982cites this paper
• Platelet activating factor (PAF) causes human platelet aggregation through the mechanism of membrane modulation.

  1982cites this paper
• Effect of furosemide on the in vitro prostaglandin biosynthesis in human platelets.

  1982cites this paper
• A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro.

  1981cites this paper